Supplement to the Petition to the DEA and FDA to Reschedule the Opioid Tramadol From Schedule IV to Schedule II
Public Citizen submitted a supplement to its November 2019 petition to the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA) to reschedule the opioid tramadol from the weakly controlled schedule IV under the Controlled Substances Act to the more tightly controlled schedule II because it is overprescribed, often misused, highly addictive and potentially deadly. The supplement adds new data from a careful study of the FDA’s Adverse Event Reporting System which revealed that tramadol use correlates with severe adverse events, including death, at rates similar to most other schedule II opioids.
November, 6, 2019, petition to the DEA and FDA to reschedule tramadol.
See Public Citizen’s other work on opioid drug issues.